Details for Patent: 10,265,287

Which drugs does patent 10,265,287 protect, and when does it expire?

Patent 10,265,287 protects VASCEPA and is included in one NDA.

This patent has forty-three patent family members in fifteen countries.

Summary for Patent: 10,265,287

Title:	Methods of reducing triglycerides and LDL-C
Abstract:	The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Inventor(s):	Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Assignee:	Amarin Pharmaceuticals Ireland Ltd
Application Number:	US15/725,617
Patent Claim Types: see list of patent claims	Use; Dosage form;

error: insufficient information

Drugs Protected by US Patent 10,265,287

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes						USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No						USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY

International Family Members for US Patent 10,265,287

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010241567
Brazil	PI1014405
Canada	2759176